Cancer Letters 2011-12-15

Identification of tumoral glial precursor cells in neuroblastoma.

Sandra Acosta, Gemma Mayol, Eva Rodríguez, Cinzia Lavarino, Katleen de Preter, Candy Kumps, Idoia Garcia, Carmen de Torres, Jaume Mora

Index: Cancer Lett. 312(1) , 73-81, (2011)

Full Text: HTML

Abstract

Neuroblastic tumors (NBT) are composed by neuroblasts and Schwannian-like stroma. The origin of these two cell subtypes remains unclear. In this study, we describe, a neuroblastic-like subpopulation in neuroblastoma (NB) coexpressing GD2 and S100A6, neuroblastic and glial lineage markers respectively. The GD2(+)/S100A6(+) neuroblastic subpopulation was found to be enriched in low risk NB, distributed around the perivascular niche. Some stromal bundles showed GD2(+)/S100A6 costaining. Metastatic bone marrow specimens also showed GD2(+)/S100A6(+) cells. During in vitro retinoic acid induced differentiation of NB cell lines, rare GD2(+)/S100A6 neuroblatic cells appeared. We conclude that GD2(+)/S100A6(+) neuroblasts may represent a tumoral glial precursor subpopulation in NBT.Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.


Related Compounds

Related Articles:

Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes.

2014-04-16

[Neuron 82(2) , 308-19, (2014)]

Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.

2014-11-01

[Int. J. Cancer 135(9) , 2199-205, (2014)]

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.

2013-04-01

[J. Mol. Med. 91(4) , 459-72, (2013)]

Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.

2013-12-15

[J. Immunol. Methods 398-399 , 51-9, (2013)]

Uterine leiomyosarcoma diffusely express disialoganglioside GD2 and bind the therapeutic immunocytokine 14.18-IL2: implications for immunotherapy.

2012-07-01

[Cancer Immunol. Immunother. 61(7) , 1149-53, (2012)]

More Articles...